All subpopulations of statin users stratified by sex, age, DM, hypertension, stroke, CAD, COPD, smoking-related disorder, CT/RT, EGFR-TKIs, EGFR-TKI response, and CT regimens before EGFR-TKI had a significantly reduced risk of death (p < 0.001) (Table 3). This evidence concerns the gene EGFR and hypertensive disorder.